| 000 | 01845 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515232341.0 | ||
| 264 | 0 | _c20101216 | |
| 008 | 201012s 0 0 eng d | ||
| 022 | _a1563-258X | ||
| 024 | 7 |
_a10.1007/s10354-010-0796-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStrehblow, Christoph | |
| 245 | 0 | 0 |
_aComparison of different biologic agents in patients with rheumatoid arthritis after failure of the first biologic therapy. _h[electronic resource] |
| 260 |
_bWiener medizinische Wochenschrift (1946) _cMay 2010 |
||
| 300 |
_a225-9 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdalimumab |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadverse effects |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 |
_aBiological Products _xadverse effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Substitution |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aDrug Tolerance |
| 650 | 0 | 4 | _aEtanercept |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xadverse effects |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 |
_aInterleukin 1 Receptor Antagonist Protein _xadverse effects |
| 650 | 0 | 4 | _aLongitudinal Studies |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHaberhauer, Guenther | |
| 700 | 1 | _aFasching, Peter | |
| 773 | 0 |
_tWiener medizinische Wochenschrift (1946) _gvol. 160 _gno. 9-10 _gp. 225-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10354-010-0796-z _zAvailable from publisher's website |
| 999 |
_c19974868 _d19974868 |
||